Neuroinflammatory phenotype in early Alzheimer's disease

Neurobiology of Aging

Volumn 34, Issue 4, 2013, Pages 1051-1059

  Sudduth, Tiffany L ^a   Schmitt, Frederick A ^a   Nelson, Peter T ^a   Wilcock, Donna M ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's; Clinical trials; Cytokines; Inflammation; Microglia

Indexed keywords

CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; SPHINGOSINE KINASE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AG1 GENE; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CD86 GENE; CEREBELLUM; CHI3L1 GENE; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; FCGAMMAR 2GENE; FCGAMMAR1 GENE; FRONTAL CORTEX; GENE; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IFN GAMMA GENE; IL 10 GENE; IL 12 GENE; IL 1RA GENE; IL 6 GENE; IL1B GENE; MICROGLIA; MRC1 GENE; NERVOUS SYSTEM INFLAMMATION; NUCLEOTIDE SEQUENCE; POLARIZATION; PRIORITY JOURNAL; SPHK1 GENE; TGF BETA GENE; TNF ALPHA GENE; UNITED STATES;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COMORBIDITY; CYTOKINES; ENCEPHALITIS; FEMALE; HUMANS; KENTUCKY; MALE; PREVALENCE;

EID: 84872337044     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.09.012     Document Type: Article

References (39)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
2. Bowler J.V., Munoz D.G., Merskey H., Hachinski V. Fallacies in the pathological confirmation of the diagnosis of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1998, 64:18-24.
3. Breitner J.C., Baker L.D., Montine T.J., Meinert C.L., Lyketsos C.G., Ashe K.H., Brandt J., Craft S., Evans D.E., Green R.C., Ismail M.S., Martin B.K., Mullan M.J., Sabbagh M., Tariot P.N. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 2011, 7:402-411.
4. Breitner J.C., Haneuse S.J., Walker R., Dublin S., Crane P.K., Gray S.L., Larson E.B. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009, 72:1899-1905.
5. Breitner J.C., Martin B.K., Meinert C.L. The suspension of treatments in ADAPT: concerns beyond the cardiovascular safety of celecoxib or naproxen. PLoS Clin. Trials 2006, 1:e41.
6. Colton C.A., Mott R.T., Sharpe H., Xu Q., Van Nostrand W.E., Vitek M.P. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J. Neuroinflammation 2006, 3:27.
7. Colton C.A., Wilcock D.M. Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 2010, 9:174-191.
8. DiCarlo G., Wilcock D., Henderson D., Gordon M., Morgan D. Intrahippocampal LPS injections reduce Abeta load in APP+PS1 transgenic mice. Neurobiol. Aging 2001, 22:1007-1012.
9. Dik M.G., Jonker C., Hack C.E., Smit J.H., Comijs H.C., Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology 2005, 64:1371-1377.
10. Edwards J.P., Zhang X., Frauwirth K.A., Mosser D.M. Biochemical and functional characterization of three activated macrophage populations. J. Leukocyte Biol. 2006, 80:1298-1307.
11. Folstein M.F., Folstein S.E., McHugh P.R. " Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatric Res. 1975, 12:189-198.
12. Guerreiro R.J., Santana I., Bras J.M., Santiago B., Paiva A., Oliveira C. Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. Neurodegener. Dis. 2007, 4:406-412.
13. Hyman B.T., Phelps C.H., Beach T.G., Bigio E.H., Cairns N.J., Carrillo M.C., Dickson D.W., Duyckaerts C., Frosch M.P., Masliah E., Mirra S.S., Nelson P.T., Schneider J.A., Thal D.R., Thies B., Trojanowski J.Q., Vinters H.V., Montine T.J. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012, 8:1-13.
14. Kammoun S., Gold G., Bouras C., Giannakopoulos P., McGee W., Herrmann F., Michel J.P. Immediate causes of death of demented and non-demented elderly. Acta Neurol. Scand. Suppl. 2000, 176:96-99.
15. Langa K.M., Foster N.L., Larson E.B. Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004, 292:2901-2908.
16. Launer L.J., Hughes T., Yu B., Masaki K., Petrovitch H., Ross G.W., White L.R. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension 2010, 55:1352-1359.
17. Launer L.J., Ross G.W., Petrovitch H., Masaki K., Foley D., White L.R., Havlik R.J. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 2000, 21:49-55.
18. Lee D.C., Rizer J., Selenica M.L., Reid P., Kraft C., Johnson A., Blair L., Gordon M.N., Dickey C.A., Morgan D. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J. Neuroinflammation 2010, 7:56.
19. Leoutsakos J.M., Muthen B.O., Breitner J.C., Lyketsos C.G. Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. Int. J. Geriatr. Psychiatry 2011, 27:364-374.
20. Levine D.A., Langa K.M. Vascular cognitive impairment: disease mechanisms and therapeutic implications. Neurotherapeutics 2011, 8:361-373.
21. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
22. Mancinella A., Mancinella M., Carpinteri G., Bellomo A., Fossati C., Gianturco V., Iori A., Ettorre E., Troisi G., Marigliano V. Is there a relationship between high C-reactive protein (CRP) levels and dementia?. Arch. Gerontol. Geriatr. 2009, 49(Suppl 1):185-194.
23. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
24. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu. Rev. Immunol. 2009, 27:451-483.
25. Moreno B., Jukes J.P., Vergara-Irigaray N., Errea O., Villoslada P., Perry V.H., Newman T.A. Systemic inflammation induces axon injury during brain inflammation. Ann. Neurol. 2011, 70:932-942.
26. Mosser D.M. The many faces of macrophage activation. J. Leukoc. Biol. 2003, 73:209-212.
27. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
28. Nelson P.T., Braak H., Markesbery W.R. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J. Neuropathol. Exp. Neurol. 2009, 68:1-14.
29. Nelson P.T., Jicha G.A., Schmitt F.A., Liu H., Davis D.G., Mendiondo M.S., Abner E.L., Markesbery W.R. Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles " do count" when staging disease severity. J. Neuropathol. Exp. Neurol. 2007, 66:1136-1146.
30. Perry V.H. Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol. 2010, 120:277-286.
31. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J.A., Tibshirani R., Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 2007, 13:1359-1362.
32. Schmitt F.A., Nelson P.T., Abner E., Scheff S., Jicha G.A., Smith C., Cooper G., Mendiondo M., Danner D.D., Van Eldik L.J., Caban-Holt A., Lovell M.A., Kryscio R.J. University of Kentucky Sanders-Brown Healthy Brain Aging volunteers: donor characteristics, procedures, and neuropathology. Curr. Alzheimer Res. 2012, 9:724-733.
33. Schmitt F.A., Wetherby M.M., Wekstein D.R., Dearth C.M., Markesbery W.R. Brain donation in normal aging: procedures, motivations, and donor characteristics from the Biologically Resilient Adults in Neurological Studies (BRAiNS) Project. Gerontologist 2001, 41:716-722.
34. Shah N.S., Vidal J.S., Masaki K., Petrovitch H., Ross G.W., Tilley C., DeMattos R.B., Tracy R.P., White L.R., Launer L.J. Midlife blood pressure, plasma beta-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension 2012, 59:780-786.
35. Sonnen J.A., Larson E.B., Walker R.L., Haneuse S., Crane P.K., Gray S.L., Breitner J.C., Montine T.J. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 2010, 75:1203-1210.
36. Sudduth T.L., Wilson J.G., Everhart A., Colton C.A., Wilcock D.M. Lithium treatment of APPSwDI/NOS2-/- mice leads to reduced hyperphosphorylated tau, increased amyloid deposition and altered inflammatory phenotype. PloS One 2012, 7:e31993.
37. Szekely C.A., Thorne J.E., Zandi P.P., Ek M., Messias E., Breitner J.C., Goodman S.N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiol. 2004, 23:159-169.
38. Wilcock D.M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K.E., Gordon M.N., Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 2003, 23:3745-3751.
39. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 2004, 1:24.